GEN Exclusives

More »

GEN News Highlights

Back to Item »

Gilead and Tibotec Ink Pact to Develop Once-Daily HIV Therapy

Product will combine Gilead’s Truvada and Tibotec’s NNRTI candidate in Phase III studies.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?